Search Result
Results for "
hepatic steatosis
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
1
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-N0341
-
|
Sirtuin
|
Metabolic Disease
|
Scopolin is a coumarin isolated from Arabidopsis thaliana (Arabidopsis) roots . Scopolin attenuated hepatic steatosis through activation of SIRT1-mediated signaling cascades .
|
-
-
- HY-151481
-
|
FXR
|
Metabolic Disease
|
FXR antagonist 1 (compound F6) is an orally active and selective intestinal FXR antagonist (IC50=2.1 μM). FXR antagonist 1 selectively inhibits intestinal FXR signalling through antagonism of intestinal FXR and feedback activation of hepatic FXR to improve hepatic steatosis, inflammation and fibrosis in NASH (nonalcoholic steatohepatitis) models. FXR antagonist 1 can be used in NASH studies .
|
-
-
- HY-N8495
-
|
Others
|
Metabolic Disease
|
4'-Hydroxyflavanone is an inhibitor of SREBP maturation and lipid synthesis. 4'-Hydroxyflavanone is a synthetic analogue of flavanone, has potential for hepatic steatosis and dyslipidemia research .
|
-
-
- HY-N0157
-
6-Carboxyuracil; Vitamin B13
|
Nucleoside Antimetabolite/Analog
Endogenous Metabolite
|
Metabolic Disease
|
Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats .
|
-
-
- HY-N0157A
-
6-Carboxyuracil zinc; Vitamin B13 zinc
|
Nucleoside Antimetabolite/Analog
Endogenous Metabolite
|
Metabolic Disease
|
Orotic acid (zinc), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid (zinc) is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid (zinc) can induce hepatic steatosis and hepatomegaly in rats .
|
-
-
- HY-D1168
-
|
Fluorescent Dye
|
Metabolic Disease
|
Oil Red O is a fat-soluble diazol dye, with a maximum absorption at 518 nm. Oil Red O stains neutral lipids and cholesteryl esters but not biological membranes. Oil Red O can be used for detecting and quantifying hepatic steatosis in mouse liver biopsies. Oil Red O staining efficiently helps to visualize the radical changes that occur in tissues as metabolic disease occurs and progresses .
|
-
-
- HY-N6869
-
|
Antibiotic
PPAR
Bacterial
Fungal
|
Infection
Metabolic Disease
Inflammation/Immunology
Cancer
|
Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .
|
-
-
- HY-N0341R
-
|
Sirtuin
|
Metabolic Disease
|
Scopolin (Standard) is the analytical standard of Scopolin. This product is intended for research and analytical applications. Scopolin is a coumarin isolated from Arabidopsis thaliana (Arabidopsis) roots . Scopolin attenuated hepatic steatosis through activation of SIRT1-mediated signaling cascades .
|
-
-
- HY-161892
-
|
FABP
|
Metabolic Disease
Inflammation/Immunology
|
FABP4-IN-4 (Compound 30) is an orally active inhibitor for FABP, with IC50 of 1.18 μM for FABP 1. FABP4-IN-4 improves the glucose tolerance, reduces the level of blood glucose, plasma lipids and hepatic inflammatory factors, attenuates hepatic steatosis, and exhibits anti-inflammatory effects in mouse diet-induced obesity models .
|
-
-
- HY-N2953
-
|
Fatty Acid Synthase (FASN)
|
Metabolic Disease
|
Borapetoside E can be isolated from T. crispa. Borapetoside E improves hyperglycemia, insulin resistance, hepatic steatosis, hyperlipidemia, and oxygen consumption in obese mice. Borapetoside E also inhibits SREBPs expression in the liver and adipose tissue .
|
-
-
- HY-N6869R
-
|
Antibiotic
PPAR
Bacterial
Fungal
|
Infection
Metabolic Disease
Inflammation/Immunology
Cancer
|
Dehydroabietic acid (Standard) is the analytical standard of Dehydroabietic acid. This product is intended for research and analytical applications. Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .
|
-
-
- HY-165069
-
Sphingomyelin (d18:1 C22:0)
|
Others
|
Others
|
N-Docosanoyl-D-erythro-sphingosylphosphorylcholine (Sphingomyelin (d18:1 C22:0)) is a compound that appears in the plasma sphingolipid profile after chronic hepatitis C virus infection. The level of this substance in plasma is associated with hepatic steatosis and may be an independent factor of hepatic steatosis.
|
-
-
- HY-W588256
-
|
Endogenous Metabolite
Acetyl-CoA Carboxylase
|
Infection
|
12-Tridecenoic acid is a metabolite of intestinal flora, which can promote the expression of acetyl-CoA carboxylase α (ACC) and inhibit the expression of carnitine palmitoyltransferase 1A (CPT1A), thereby aggravating hepatic steatosis. 12-Tridecenoic acid aggravates hepatic steatosis by affecting the ACC-CPT1A axis .
|
-
-
- HY-141623
-
|
Arrestin
|
Metabolic Disease
|
SRI-37330 hydrochloride is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor. SRI-37330 hydrochloride inhibits glucagon secretion and function, reduces hepatic glucose production and reverses hepatic steatosis. SRI-37330 hydrochloride can be used for type 2 diabetes research .
|
-
-
- HY-142114
-
|
Arrestin
|
Metabolic Disease
|
SRI-37330 is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor. SRI-37330 inhibits glucagon secretion and function, reduces hepatic glucose production and reverses hepatic steatosis. SRI-37330 can be used for type 2 diabetes research .
|
-
-
- HY-N8144
-
|
Others
|
Cardiovascular Disease
|
Niga-ichigoside F1, an orally active ursane triterpenoid, has antihyperlipidemic and antioxidant activities. Niga-ichigoside F1 can prevent high-fat diet (HFD)-induced hepatic steatosis .
|
-
-
- HY-151959
-
|
FXR
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC50 value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD) .
|
-
-
- HY-W505108
-
|
Drug Metabolite
|
Metabolic Disease
|
2,3-Dihydroxypropyl pentadecanoate is a monoacylglycerol that is found in wheat bran extracts. 2,3-Dihydroxypropyl pentadecanoate levels are increased in a HepaRG cell-based model of hepatic steatosis induced by BSA-conjugated palmitate .
|
-
-
- HY-163531
-
|
Others
|
Metabolic Disease
|
GPR41 modulator 2 (Compound 10bx) exhibits agonistic activity for G protein-coupled receptor (GPR41) .
|
-
-
- HY-172105
-
|
PPAR
|
Metabolic Disease
Inflammation/Immunology
|
Anti-NASH agent 2 (compound 21) is an inhibitor of de novo adipogenesis activity and α-SMA gene expression. Anti-NASH agent 2 improves hepatic steatosis, edema, inflammatory infiltrates, and liver fibrosis in NASH mouse models .
|
-
-
- HY-W127408
-
|
Biochemical Assay Reagents
Endogenous Metabolite
|
Others
|
1,2,3-Tripalmitoleoyl-rac-glycerol is a triacylglycerol containing palmitoleic acid at the sn-1, sn-2 and sn-3 positions. It reduces erythrocyte deformability in a concentration-dependent manner in the Reid filtration assay. Hepatic levels of 1,2,3-tripalmitoleoyl-rac-glycerol are increased in a JAK2L mouse model of hepatic steatosis. 1,2,3-Tripalmitoleoyl-rac-glycerol plasma levels are reduced in patients with predialysis renal disease.
|
-
-
- HY-112812
-
|
Stearoyl-CoA Desaturase (SCD)
|
Metabolic Disease
|
SCD1 inhibitor-1 (Compound 48) is an orally active and liver-selective inhibitor of stearoyl-CoA desaturase 1 (SCD1) with an IC50 of 8.8 nM for recombinant human SCD1 enzyme. SCD1 inhibitor-1 can be used in the study of diseases such as diabetes, hepatic steatosis and obesity .
|
-
-
- HY-N0261
-
|
TNF Receptor
COX
|
Cardiovascular Disease
Inflammation/Immunology
|
Aurantio-obtusin is a anthraquinone compound that can be extracted from cassia seed. Aurantio-obtusin has the effects of decreasing blood pressure, decreasing blood lipids and anti-inflammatory.Aurantio-obtusin is an orally active vasodilator. Aurantio-obtusin ameliorates hepatic steatosis through AMPK/ autophagy- and AMPK/TFEB mediated inhibition of lipid accumulation .
|
-
-
- HY-N0157C
-
6-Carboxyuracil potassium; Vitamin B13 potassium
|
Endogenous Metabolite
DNA/RNA Synthesis
|
Metabolic Disease
|
Orotic acid potassium (Vitamin B13 potassium) is a precursor of pyrimidine bases and is involved in the synthesis of DNA and RNA. Orotic acid potassium stimulates the growth of animals, plants and microorganisms, participates in carbohydrate metabolism, and is necessary for the growth and life activities of organisms. Orotic acid potassium is a measurement indicator in routine newborn screening for urea cycle abnormalities. Orotic acid potassium can cause hepatic steatosis and hepatomegaly in rats .
|
-
-
- HY-N0157R
-
6-Carboxyuracil (Standard); Vitamin B13 (Standard)
|
Nucleoside Antimetabolite/Analog
Endogenous Metabolite
|
Metabolic Disease
|
Orotic acid (Standard) is the analytical standard of Orotic acid. This product is intended for research and analytical applications. Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats .
|
-
-
- HY-N0261R
-
|
TNF Receptor
COX
|
Cardiovascular Disease
Inflammation/Immunology
|
Aurantio-obtusin (Standard) is the analytical standard of Aurantio-obtusin. This product is intended for research and analytical applications. Aurantio-obtusin is a anthraquinone compound that can be extracted from cassia seed. Aurantio-obtusin has the effects of decreasing blood pressure, decreasing blood lipids and anti-inflammatory.Aurantio-obtusin is an orally active vasodilator. Aurantio-obtusin ameliorates hepatic steatosis through AMPK/ autophagy-and AMPK/TFEB mediated inhibition of lipid accumulation .
|
-
-
- HY-N0157S1
-
6-Carboxyuracil-13C,15N2 monohydrate; Vitamin B13-13C,15N2 monohydrate
|
Nucleoside Antimetabolite/Analog
Endogenous Metabolite
|
Metabolic Disease
|
Orotic acid- 13C, 15N2 (monohydrate) is the 13C and 15N labeled Orotic acid[1]. Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats[2][3][4].
|
-
-
- HY-161926
-
|
PPAR
|
Metabolic Disease
|
YGT-31 is a modulator for PPARγ with an IC50 of 1.72 μM, and a Ki of 0.62 μM. YGT-31 reduces blood glucose levels and improves insulin resistance in db/db mice type 2 diabetes models, through inhibition of CDK5-mediated PPARγ-Ser273 phosphorylation. YGT-31 exhibits anti-hepatic steatosis effect in mice non-alcoholic fatty liver disease (NAFLD) model .
|
-
-
- HY-N8495R
-
-
-
- HY-W018791
-
DDB
|
HBV
Autophagy
Cytochrome P450
Atg8/LC3
p62
P-glycoprotein
|
Infection
Cardiovascular Disease
Cancer
|
Bifendate (DDB), extracted from Schisandrae chinensis, is an orally active anti-HBV agent against chronic hepatitis B. Bifendate inhibits ATG5-dependent autophagy and attenuates oleic acid-induced lipid accumulation with anti-oxidant properties in vitro. Bifendate can decrease alanine transaminase (ALT) level in mice. Bifendate attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Bifendate potently increases the activity of cytochrome proteins (CYPs) and reverse P-gp-mediated multi-drug resistance (MDR) .
|
-
-
- HY-122591
-
PTUPB
1 Publications Verification
|
COX
|
Metabolic Disease
Cancer
|
PTUPB is a potent and dual sEH and COX-2 enzymes inhibitor with IC50 of 0.9 nM and 1.26 μM, respectively .
|
-
-
- HY-141645
-
WS070117
|
AMPK
TGF-β Receptor
NF-κB
JNK
AP-1
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
IMM-H007 (WS070117) is an orally active and potent AMPK (AMP-activated protein kinase) activator and TGFβ1 (transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation of AMPK. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis .
|
-
-
- HY-134988
-
|
FXR
Phosphatase
Cytochrome P450
|
Inflammation/Immunology
|
EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC50 values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-D1168
-
|
Fluorescent Dyes/Probes
|
Oil Red O is a fat-soluble diazol dye, with a maximum absorption at 518 nm. Oil Red O stains neutral lipids and cholesteryl esters but not biological membranes. Oil Red O can be used for detecting and quantifying hepatic steatosis in mouse liver biopsies. Oil Red O staining efficiently helps to visualize the radical changes that occur in tissues as metabolic disease occurs and progresses .
|
Cat. No. |
Product Name |
Type |
-
- HY-N0157C
-
6-Carboxyuracil potassium; Vitamin B13 potassium
|
Cell Assay Reagents
|
Orotic acid potassium (Vitamin B13 potassium) is a precursor of pyrimidine bases and is involved in the synthesis of DNA and RNA. Orotic acid potassium stimulates the growth of animals, plants and microorganisms, participates in carbohydrate metabolism, and is necessary for the growth and life activities of organisms. Orotic acid potassium is a measurement indicator in routine newborn screening for urea cycle abnormalities. Orotic acid potassium can cause hepatic steatosis and hepatomegaly in rats .
|
-
- HY-W127408
-
|
Drug Delivery
|
1,2,3-Tripalmitoleoyl-rac-glycerol is a triacylglycerol containing palmitoleic acid at the sn-1, sn-2 and sn-3 positions. It reduces erythrocyte deformability in a concentration-dependent manner in the Reid filtration assay. Hepatic levels of 1,2,3-tripalmitoleoyl-rac-glycerol are increased in a JAK2L mouse model of hepatic steatosis. 1,2,3-Tripalmitoleoyl-rac-glycerol plasma levels are reduced in patients with predialysis renal disease.
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-N0157S1
-
|
Orotic acid- 13C, 15N2 (monohydrate) is the 13C and 15N labeled Orotic acid[1]. Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats[2][3][4].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: